The FDA is weighing whether to approve MDMA for PTSD. Here’s what that could look like for patients.
Ahead of a key meeting Tuesday to weigh the potential approval of midomafetamine, or MDMA, for patients with post-traumatic stress disorder, the Food and Drug Administration is proposing a new set of restrictions on how eligible patients would be able to get the drug. Details of the FDA’s proposal were published Friday in a set
Read More